We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WWD:NASDAQWoodward, Inc. Analysis

Data as of 2026-05-11 - not real-time

$369.93

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Woodward, Inc. delivered a robust Q1 performance with revenue climbing 23.4% year‑over‑year to $3.99 B and margins expanding to a 28.5% gross, 15.4% operating and 12.9% profit margin, underscoring strong operating leverage. EPS accelerated to $8.36 trailing and $10.74 forward, yet the stock trades at a lofty PE of 44.25, well above the aerospace & defense industry average of 29.9, and the DCF‑derived fair value sits near $101, suggesting the market is pricing in a significant premium. The dividend remains modest at 0.35% with a low payout ratio of 13.9%, indicating sustainable cash generation, while the balance sheet shows manageable leverage (debt‑to‑equity ~46%).
Technical indicators show the price (≈$370) hovering just below the 20‑day SMA (≈$375) and the 50‑day SMA (≈$374), with a neutral RSI of 48.9 and a bearish MACD histogram, hinting at short‑term downside pressure. Nonetheless, volume is rising, beta is elevated (~1.23) and 30‑day volatility exceeds 43%, reflecting heightened market sensitivity. Analyst sentiment is overwhelmingly positive (strong‑buy, median target $438), implying an 18% upside potential despite the current overvaluation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and rising volume
  • Bearish MACD and price below short‑term moving averages
  • High short‑term volatility and beta

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and expanding margins
  • Analyst consensus strong‑buy with median target $438
  • Sustained cash flow and low dividend payout ratio

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Durable position in aerospace and defense with long‑term contracts
  • Valuation premium relative to DCF fair value
  • Stable dividend sustainability and manageable leverage

Key Metrics & Analysis

Financial Health

Revenue Growth23.40%
Profit Margin12.85%
P/E Ratio44.3
ROE21.13%
ROA8.01%
Debt/Equity46.16
P/B Ratio8.5
Op. Cash Flow$564.2M
Free Cash Flow$194.1M
Industry P/E29.9

Technical Analysis

TrendBullish
RSI48.9
Support$347.08
Resistance$407.00
MA 20$375.08
MA 50$374.25
MA 200$308.14
MACDBearish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

Fair Value$100.78
Target Price$437.30
Upside/Downside18.21%
GradeOvervalued
TypeGrowth
Dividend Yield0.35%

Risk Assessment

Beta1.23
Volatility43.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.